Cambridge-based Axoft is taking its brain-implant tech on a very global tour. The Harvard-bred startup announced this week that it temporarily implanted its soft neural probe in a patient in Shanghai while also closing a $55 million Series A funding round. The disclosure stands out, since U.S. firms rarely talk publicly about human-testing partnerships in China.
The Massachusetts company said the round was led by C.P. Group Innovation and brings its total financing to more than $60 million. Axoft plans to use the cash to expand clinical trials and build out manufacturing capacity. In a company press release carried by BioSpace, the firm spotlighted its soft "Fleuron" material and said its implants have been used temporarily in 11 patients so far.
Shanghai Test Is Uncommon For A U.S. Startup
As reported by The Boston Globe, the Shanghai procedure was conducted through a local partner, but Axoft is not naming the partner or the hospital involved. Chief executive Paul Le Floch told the Globe the company plans to enroll more patients in China this year and to run multiple clinical trials there, signaling that Shanghai was not a one-off experiment.
From Harvard Lab To Human Trials
Axoft's Fleuron probes trace back to research at Harvard led by Jia Liu and Paul Le Floch, with Tianyang Ye developing the nanoelectronics, according to the Harvard Gazette. The Gazette reported that the company completed an early human study at a Panama clinic in 2025 and described the material as reducing scarring while enabling longer, higher-density recordings.
Why This Matters
Neurotechnology is increasingly framed as a strategic contest between nations, and cross-border testing raises hard questions about oversight, data access, and export controls. The Boston Globe noted that U.S. defense research dollars and investment from a CIA-founded venture fund have already flowed into the brain-computer interface field, which only complicates the politics around partnerships in China.
Next Steps In Cambridge
Back home, Axoft told investors it plans to build a GMP cleanroom in the Boston area, expand its engineering and manufacturing teams, and aims to file with the U.S. Food and Drug Administration next year. The company said the fresh capital will support global clinical work and mass production of Fleuron implants, according to BioSpace.
